PROTAC B03 induced CDK9 degradation in vivo in mouse models of acute myeloid leukemia (AML,) and showed acceptable pharmacokinetic properties with a plasma half-life of more than 1.3h after a single intravenous injection of 5 mg/kg [28]. The gene discussed is CDK9; the disease is acute myeloid leukemia.